Feb 13, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 16, 2019
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors
Dec 12, 2019
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 07, 2019
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Jul 24, 2019
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jun 25, 2019
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
May 06, 2019
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Apr 01, 2019
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
Mar 14, 2019
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Jan 30, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Jan 22, 2019
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
Nov 13, 2018
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Oct 01, 2018
SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
Aug 09, 2018
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update